Bottom line
FPHAX vs IXJ: the short answer
FPHAX (Pharmaceuticals Portfolio) and IXJ (iShares Global Healthcare ETF) are quite different portfolios: only about 36% of their top holdings (by weight) are shared.
But IXJ is far broader, holding 124 positions to 57 for FPHAX, so beyond the top names it adds exposure FPHAX doesn't have.
IXJ is cheaper at 0.38% vs 0.67% — a difference of $29 a year per $10,000 invested.
Over five years, FPHAX returned +12.6% a year vs +6.4% for IXJ (reporting dates differ).
Updated Nov 19, 2026
FPHAX vs IXJ side by side
| FPHAX | IXJ | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Fidelity | iShares |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.67% | 0.38% |
| Annual cost per $10k | $67 | $38 |
| 10-yr cost on $10k (prospectus) | $835 | $480 |
| Max front load | — | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +30.3% | +14.9% |
| 5-yr return (annualized) | +12.6% | +6.4% |
| 10-yr return (annualized) | +10.0% | +8.2% |
| Best quarter | +18.5% | +13.6% |
| Worst quarter | −13.6% | −11.8% |
| Net assets (fund) | $1.5B | $3.8B |
| Number of holdings | 57 | 124 |
| Portfolio turnover | 77% | 2% |
| Returns as of | Apr 30, 2026 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FPHAX | IXJ | Difference |
|---|---|---|---|
| 2025 | +30.3% | +14.9% | +15.4% |
| 2024 | +9.4% | +0.6% | +8.8% |
| 2023 | +12.5% | +3.5% | +9.0% |
| 2022 | +1.0% | −4.7% | +5.7% |
| 2021 | +11.8% | +19.5% | −7.7% |
| 2020 | +11.1% | +12.5% | −1.4% |
| 2019 | +31.6% | +23.4% | +8.3% |
| 2018 | +5.8% | +2.9% | +3.0% |
| 2017 | +10.7% | +20.3% | −9.7% |
| 2016 | −16.3% | −6.2% | −10.1% |
Source: Fund prospectus bar charts
Holdings overlap
6 of FPHAX's top 25 holdings also appear in IXJ's top 25.
| Holding | FPHAX | IXJ |
|---|---|---|
| ELI LILLY and CO | 28.78% | 10.93% |
| MERCK and CO INC | 4.74% | 4.12% |
| Roche Holding Ag | 4.54% | 3.75% |
| Astrazeneca Plc | 4.22% | 3.76% |
| Gilead Sciences Inc | 3.97% | 2.04% |
| JOHNSON and JOHNSON | 3.77% | 7.04% |
Source: SEC Form N-PORT
FPHAX top 10
- ELI LILLY and CO — 28.78%
- Gsk Plc — 8.17%
- Viatris Inc — 5.45%
- Ucb Sa — 5.09%
- MERCK and CO INC — 4.74%
- Roche Holding Ag — 4.54%
- Legend Biotech Corp — 4.53%
- Astrazeneca Plc — 4.22%
- Elanco Animal Health Inc — 4.15%
- Jazz Pharmaceuticals Plc — 4.09%
IXJ top 10
- Eli Lilly And Company — 10.93%
- Johnson & Johnson — 7.04%
- Abbvie Inc. — 5.12%
- Unitedhealth Group Incorporated — 4.40%
- Merck & Co., Inc. — 4.12%
- Astrazeneca Plc — 3.76%
- Roche Holding AG — 3.75%
- Novartis AG — 3.71%
- Amgen Inc. — 2.54%
- Thermo Fisher Scientific Incorporated — 2.42%
FAQ
What is the difference between FPHAX and IXJ?
Which is cheaper, FPHAX or IXJ?
Should I own both FPHAX and IXJ?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.